We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Mineral Density in Pediatric Epilepsy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00204815
First Posted: September 20, 2005
Last Update Posted: October 5, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
University of Wisconsin, Madison
September 12, 2005
September 20, 2005
October 5, 2015
January 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00204815 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bone Mineral Density in Pediatric Epilepsy
Bone Mineral Density in Pediatric Epilepsy: AED-Specific and Duration of Treatment-Specific Effects
What are the effects of the currently used AEDs on bone mineralization in children and adolescents between the ages of 8 to 18? This is a pilot observational study using DEXA scans to measure bone mineral density in 100 patients The primary objective is to collect preliminary data on bone mineral density, body weight, dietary calcium intake, and activity level.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Pediatric subjects with generalized or partial seizures
Epilepsy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
98
October 2007
Not Provided

Inclusion Criteria:

  • diagnosis of generalized or partial seizures with or without generalization or a diagnosis of generalized seizures as defined in the International League Against Epilepsy

Exclusion Criteria:

  • steroid use
  • chronic disease other than epilepsy
Sexes Eligible for Study: All
8 Years to 18 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00204815
2004-0015
No
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
GlaxoSmithKline
Principal Investigator: Raj Sheth, MD University of Wisconsin, Madison
University of Wisconsin, Madison
June 2008